GLP-1 RA Therapy for IBD: Weight Loss and Clinical Outcomes
GLP-1 receptor agonist inflammatory bowel disease therapy offers promising weight loss and metabolic improvements. This approach combines pharmacotherapy with lifestyle changes for better clinical outcomes. Patients with IBD may benefit from this…
Marijuana Use and Lower Obesity Rates: A Correlation, Not a Cure
The marijuana use obesity correlation shows obese individuals report 35% lower marijuana use than non-obese adults. This association is consistent but does not prove causation. Understanding this correlation helps clarify population-level trends without…
Cancer Patients With Medical Marijuana Cards Less Likely to Receive Excess Antiemetics, Arkansas Study Finds
A study of cancer patients found medical marijuana cardholder antiemetic overuse was significantly lower during chemotherapy. This suggests a potential role for cannabis in reducing excess antiemetic prescriptions. Further research is needed to confirm…
Marijuana Users Have Lower Obesity Rates, But Does the Drug Cause This?
Marijuana use obesity prevalence BRFSS data from 2016 to 2022 shows a consistent inverse association between marijuana use and obesity rates. This pattern is observed across demographic groups but does not prove causation. Understanding this relationship…
Cannabis Users Spend Less Time in Epilepsy Monitoring Units—But the Reasons Are Unclear
Epilepsy monitoring unit cannabis use was linked to a shorter length of stay compared to non-users. Cannabis users showed higher event capture rates but also increased psychiatric comorbidities. These findings highlight the complexity of cannabis use in…
Cannabis stigma and symptom management considerations in cancer survivors: a mixed-methods exploration of patient perspectives.
This study aims to assess for indications of stigma and attitudes toward cannabis among cancer survivors (CS) who use or consider the use of cannabis. This s...
Medicinal Cannabis Prescription Before an Inpatient Psychiatric Admission: A Retrospective Observational Audit.
Prescribing of medicinal cannabis has expanded in Australia; however, evidence for benefit in psychiatric populations is limited. The goal of this study was ...
Leveraging NCI’s Collaborative Efforts to Understand Cannabis Use in Cancer
Cannabis use cancer benefits harms are increasingly studied for symptom management among patients with cancer. The National Cancer Institute leads collaborative efforts to evaluate these effects. This research aims to clarify both benefits and potential…
GLP-1 Receptor Agonist: Why Some Patients Don’t Respond
GLP-1 drug resistance explains why some patients do not respond well to receptor agonist therapy. Genetic variation plays a key role in treatment response variability. Understanding this helps clinicians tailor diabetes and obesity management.
GLP-1 Receptor Agonist Benefits in Cardiac Interventions
GLP-1 Clinical Relevance #48Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical TrialObservational StudyCardiovascular InterventionTirzepatideCardiologyAdults…